NDAINHALATIONAEROSOL, METERED
Approved
Jan 2023
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
2
Data completeness
7/8 — Comprehensive
AIRSUPRA (albuterol sulfate and budesonide) by AstraZeneca is corticosteroid hormone receptor agonists [moa]. Approved for asthma. First approved in 2023.
Drug data last refreshed 17h ago · AI intelligence enriched 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AIRSUPRA is a metered-dose inhaler combining albuterol sulfate (short-acting beta-2 agonist) and budesonide (inhaled corticosteroid) for asthma treatment. It provides rapid bronchodilation plus anti-inflammatory control in a single device. The combination targets both acute symptoms and underlying airway inflammation.
$0.925MPart D
Peak3.6 years to LOEProduct is in early peak lifecycle with modest initial uptake; commercial teams should expect gradual market expansion and stabilization over next 18-24 months.
Mechanism of Action
Corticosteroid Hormone Receptor Agonists
Pharmacologic Class:
Corticosteroid
Indications (1)
Clinical Trials (2)
GRANITE: Airsupra Effectiveness in the Real World
Started Jul 2025
4,060 enrolled
Asthma
Study to Investigate Changes in Airway Inflammation, Symptoms, and Rescue Therapy Utilization With AIRSUPRA Compared to Albuterol as Needed in Adults With Mild Asthma
Started Sep 2024
101 enrolled
Mild Asthma
Why This Matters for Your Career
Worked on AIRSUPRA at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.